Relmada Therapeutics is a clinical stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system CNS diseases. The Company has a diversified portfolio of four products at various stages of development, including d Methadone dextromethadone, REL , an N methyl D aspartate NMDA receptor antagonist for depression and neuropathic pain LevoCap ER REL , an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol oral buprenorphine BuTab, REL , an oral dosage form of the opioid analgesic buprenorphine and topical mepivacaine MepiGel, REL , an orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company s product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs.
Quote | Relmada Therapeutics Inc. (OTCMKTS:RLMD)
Last: | $ |
---|---|
Change Percent: | -1.10% |
Open: | $42.00 |
Close: | $41.51 |
High: | $42.475 |
Low: | $41.11 |
Volume: | 45,680 |
Last Trade Date Time: | 02/12/2020 04:57:15 pm |
News | Relmada Therapeutics Inc. (OTCMKTS:RLMD)
2024-03-21 18:57:54 ET Summary RLMD plans to report results from the phase 3 Reliance II study of REL-1017, as an adjunctive treatment for major depressive disorder, in H2 2024. The current timeline for completion of enrolment in Reliance II may suggest a slight slippage, but my p...
2024-03-20 12:25:51 ET More on Mid-day movers & stocks. Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript Personalis Q4 2023 Earnings Preview XTI Aircraft that will merge with Inpixon gets Chinese patent for an aircraft Seeking Alpha’s Quant...
Message Board Posts | Relmada Therapeutics Inc. (OTCMKTS:RLMD)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $RLMD News Article - Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments | whytestocks | investorshangout | 01/12/2023 3:25:46 PM |
whytestocks: $RLMD News Article - Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorm | whytestocks | investorshangout | 01/09/2023 7:50:50 PM |
whytestocks: $RLMD News Article - Relmada Therapeutics Receives FDA Fast Track Designation for REL-1 | whytestocks | investorshangout | 08/09/2022 11:10:57 PM |
whytestocks: $RLMD News Article - Relmada Therapeutics Announces Publication of REL-1017 Preclinical | whytestocks | investorshangout | 04/29/2022 5:15:52 PM |
This stock just wont quit. Love it! | Glider549 | investorshub | 04/03/2022 11:17:19 PM |
News, Short Squeeze, Breakout and More Instantly...
Relmada Therapeutics Inc. Company Name:
RLMD Stock Symbol:
OTCMKTS Market:
Relmada Therapeutics Inc. Website:
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results PR Newswire CORAL GABLES, Fla. , March 19, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addre...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024 PR Newswire CORAL GABLES, Fla. , March 12, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biote...